Ruxolitinib therapy followed by reduced-intensity conditioning for hematopoietic cell transplantation for myelofibrosis: Myeloproliferative Disorders Research Consortium 114 study

Ruxolitinib therapy followed by reduced-intensity conditioning for hematopoietic cell transplantation for myelofibrosis: Myeloproliferative Disorders Research Consortium 114 study

We evaluated the feasibility of ruxolitinib therapy followed by a reduced-intensity conditioning (RIC) regimen for patients with myelofibrosis (MF) undergoing transplantation in a 2-stage Simon phase II trial. The aims were to decrease the incidence of graft failure (GF) and nonrelapse mortality (NR...

وصف كامل

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Gupta, V, Kosiorek, H, Mead, A, Klisovic, R, Galvin, J, Berenzon, D, Yacoub, A, Viswabandya, A, Mesa, R, Goldberg, J, Price, L, Salama, M, Weinberg, R, Rampal, R, Farnoud, N, Dueck, A, Mascarenhas, J, Hoffman, R
التنسيق: Journal article
اللغة:English
منشور في: Elsevier 2018

مواد مشابهة

مواد مشابهة